0000000000424941

AUTHOR

Paola Conti

0000-0003-2140-0567

showing 4 related works from this author

Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation.

2015

Novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation were developed; some of them possess K(i) values in the micromolar range. We studied the structure-activity relationship of these derivatives and we performed docking studies, which allowed us to find out the key interactions established by the inhibitors with the target enzyme. Biological results indicate that the nature of the P2 and P3 substituents and their binding to the S2/S3 pockets is strictly interdependent.

InhibitorMolecular modelCell SurvivalClinical BiochemistryTrypanosoma brucei bruceiAntiprotozoal AgentsPharmaceutical ScienceMolecular modelingCysteine Proteinase InhibitorsBiochemistryCell Linechemistry.chemical_compoundMiceStructure-Activity RelationshipCysteine ProteasesDrug DiscoveryAnimalsMolecular Biology3-Bromo isoxazolinechemistry.chemical_classificationDipeptide-likeDipeptideBinding SitesOrganic ChemistryDipeptidesIsoxazolesCombinatorial chemistryProtein Structure TertiaryMolecular Docking SimulationCysteine EndopeptidasesEnzymeRhodesainchemistryWarheadDocking (molecular)Drug DesignMolecular MedicineRhodesain Dipeptide-like 3-Bromo isoxazoline Inhibitor Molecular modelingBioorganicmedicinal chemistry
researchProduct

Synthesis and biological evaluation of papain-family cathepsin L-like cysteine protease inhibitors containing a 1,4-benzodiazepine scaffold as antipr…

2014

Novel papain-family cathepsin L-like cysteine protease inhibitors endowed with antitrypanosomal and antimalarial activity were developed, through an optimization study of previously developed inhibitors. In the present work, we studied the structure-activity relationships of these derivatives, with the aim to develop new analogues with a simplified and more synthetically accessible structure and with improved antiparasitic activity. The structure of the model compounds was significantly simplified by modifying or even eliminating the side chain appended at the C3 atom of the benzodiazepine scaffold. In addition, a simple methylene spacer of appropriate length was inserted between the benzod…

Trypanosomamedicine.drug_classPeptidomimeticStereochemistryAntiparasiticCell SurvivalCathepsin LAntiprotozoal AgentsCysteine Proteinase InhibitorsBiochemistryCathepsin BCell LineCathepsin Lchemistry.chemical_compoundBenzodiazepinesMiceStructure-Activity RelationshipDrug DiscoverymedicineMoietyAnimalsGeneral Pharmacology Toxicology and PharmaceuticsPharmacologyCathepsinbiologyOrganic ChemistryCombinatorial chemistryCysteine proteasePapainantiprotozoal agents; inhibitors; Malaria; Peptidomimetics; structure-activity relationshipsCysteine EndopeptidaseschemistryAntiprotozoalbiology.proteinMolecular MedicineProtein BindingChemMedChem
researchProduct

Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead

2013

Novel rhodesain inhibitors were obtained by combining an enantiomerically pure 3-bromoisoxazoline warhead with a specific peptidomimetic recognition moiety. All derivatives behaved as inhibitors of rhodesain, with low micromolar Ki values. Their activity against the enzyme was found to be paralleled by an in vitro antitrypanosomal activity, with IC50 values in the mid-micromolar range. Notably, a preference for parasitic over human proteases, specifically cathepsins B and L, was observed.

ProteasesStereochemistryPeptidomimeticCathepsin LMolecular ConformationStereoisomerismCysteine Proteinase InhibitorsBiologyCrystallography X-RayBiochemistryCysteine Proteinase InhibitorsCathepsin BCathepsin LinhibitorsDrug DiscoveryHumansMoietyGeneral Pharmacology Toxicology and PharmaceuticstrypanosomarhodesainPharmacologychemistry.chemical_classificationOrganic ChemistryStereoisomerismIsoxazolesisoxazolinesCombinatorial chemistryIn vitroCysteine EndopeptidasesEnzymechemistrypeptidomimeticsbiology.proteinMolecular Medicineinhibitors; isoxazolines; peptidomimetics; rhodesain; trypanosomaProtein Binding
researchProduct

CCDC 963005: Experimental Crystal Structure Determination

2013

Related Article: Roberta Ettari, Lucia Tamborini, Ilenia C. Angelo, Silvana Grasso, Tanja Schirmeister, Leonardo Lo Presti, Carlo De Micheli, Andrea Pinto, Paola Conti|2013|ChemMedChem|8|2070|doi:10.1002/cmdc.201300390

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(3aS6aS)-t-Butyl-3-bromo-66a-dihydro-3aH-pyrrolo[34-d]isoxazole-5(4H)-carboxylateExperimental 3D Coordinates
researchProduct